# 2025-01840: OTC Drug Rules Delayed to March: Presidential Review Pause

2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-01-27, effective 2025-03-21; deemed significant under Executive Order 12866; PRIA reads it as touching household money (as of 2026-09-21).

- Canonical: https://policyrisk.com/federal-register/2025-01840
- As of: 2026-09-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-01840
- Title: Nonprescription Drug Product With an Additional Condition for Nonprescription Use
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 8173
- Published: 2025-01-27
- Effective: 2025-03-21
- Comments close: not stated
- Significant: yes (FR_METADATA)
- Touches household money: yes
- Regulation identifier numbers: 0910-AH62
- Last updated: 2026-09-21

## In one line

OTC Drug Rules Delayed to March: Presidential Review Pause

## Summary

The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.

## Abstract

In accordance with the memorandum of January 20, 2025, from the President, entitled "Regulatory Freeze Pending Review," the effective date of the final rule, entitled "Nonprescription Drug Product With an Additional Condition for Nonprescription Use," (ACNU) is delayed until March 21, 2025.

## Effects PRIA read

- Effective Date Delayed to March 21, 2025: mixed, low. The FDA delayed the final rule "Nonprescription Drug Product With an Additional Condition for Nonprescription Use" from the original effective date of January 27, 2025 to March 21, 2025. Drug makers, sellers, and consumers should note the new start date and use the additional time to plan for the u…
- Separate NDA/ANDA Required for ACNU Products: cost, medium. The final rule requires applicants seeking approval for a nonprescription drug product with an additional condition for nonprescription use (ACNU) to submit a separate new drug application (NDA) or abbreviated new drug application (ANDA) rather than a supplement when a prescription version is alrea…
- New Labeling Content and Format Rules: benefit, medium. The final rule establishes specific labeling requirements for nonprescription drug products with an ACNU, including the content and format of specific labeling statements, and it also provides an exemption from the requirement to be labeled with adequate directions for use if certain labeling condi…
- Postmarketing ACNU Failure Reporting: cost, medium. The final rule requires an applicant to submit a postmarketing report if there is an ACNU failure and states that FDA will refuse to approve an application for a nonprescription drug product with an ACNU if the application fails to meet applicable requirements.
- ACNU Can Make OTC Products Marketable: benefit, medium. The final rule clarifies that an ACNU constitutes a meaningful difference that can make a nonprescription drug product safe and effective for use without a licensed practitioner; therefore a prescription drug product and a nonprescription drug product with an ACNU and the same active ingredient may…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2026-22883](https://policyrisk.com/federal-register/2026-22883): Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency; Guidance for Industry and…, 2026-11-10

## Sources
- [2025-01840 on federalregister.gov](https://www.federalregister.gov/documents/2025/01/27/2025-01840/nonprescription-drug-product-with-an-additional-condition-for-nonprescription-use)
- [2025-01840 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-01-27/pdf/2025-01840.pdf)

## Related
- [Previous: 2025-01832, Federal Motor Vehicle Safety Standards; Automatic Emergency Braking Systems for…](https://policyrisk.com/federal-register/2025-01832)
- [Next: C1-2024-30824, Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Inf…](https://policyrisk.com/federal-register/C1-2024-30824)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-01840 (as of 2026-09-21).
